India 
USA
UK
South Africa
Australia
Philippines
Germany
Netherlands
Mexico
Brazil
Canada
Lupin has expanded and grown manifold since its inception in 1968. We have operations in 11 countries across six continents, allowing for safe and reliable delivery of medicines to our patients across 100+ countries.
India
Lupin’s journey began in India, when Dr Desh Bandhu Gupta (fondly called DBG) established the company in 1968. From one facility in Aurangabad in 1979, the company now has 11 state-of-the-art manufacturing facilities across the country. Scientists and R&D personnel at the company’s two research centres in Pune and Aurangabad leverage cutting-edge technology to provide unique solutions, including those in the field of high quality affordable biosimilars. Along with the commercial enterprise, DBG also founded the Lupin Human Welfare & Research Foundation, which promotes holistic rural development in India.
USA
Lupin Pharmaceuticals Inc., established in 2003 in Baltimore, Maryland, currently has five offices along the US East Coast with its salesforce across the country. Lupin is present in the US through manufacturing, research and development, and commercial divisions for generics, complex generics, biosimilars and branded pharmaceuticals. In 2015, the company set up the Center of Excellence for Inhalation Research in Coral Springs, Florida. Subsequently, it acquired Novel Laboratories, Inc. to create Lupin Somerset — its first manufacturing facility in the US. In 2017-18, Lupin achieved a milestone when US revenues crossed $1 billion.
UK
Lupin Healthcare, our subsidiary in the UK has a portfolio consisting of high quality generics with a focus on anti-retroviral and oral contraceptives. In January 2019, we launched our first set of medicines in the neuromuscular space for the UK market. The entrepreneurial spirit, external focus and pipeline strength transitions Lupin in the U.K. from standard generics through to a more specialist organization partnering with the NHS to deliver value.
South Africa
Pharma Dynamics, our subsidiary in South Africa, is committed to expanding access to effective, affordable healthcare and helping create a healthy future for all South Africans. Our quality generic medicines offer patients cost savings of up to 70%. We also invest in various wellness programmes to support patients on their journey to holistic wellness.
Australia
Generic Health, Lupin’s subsidiary in Australia, is among the fastest growing pharmaceutical companies in the country. It is a leading provider of high-quality generic prescription, injectable and over-the-counter medicines, supplying to pharmacies and hospitals across Australia. We are committed to supporting the health and wellbeing of all Australians through our comprehensive product range, competitive pricing, and healthcare expertise.
Philippines
Multicare, Lupin’s subsidiary in the Philippines, is among the top five branded generic companies in the country. It is committed to providing high-quality products that enhance healthcare for patients and deliver greater value for medical professionals. Multicare strategically focuses on therapeutic areas and specialties, and has established a reputation in women’s health, especially in their journey of becoming mothers. Other areas of focus for the company include rheumatology, respiratory, oncology, neuroscience, diabetes, gastroenterology, pediatrics, and nephrology.
Germany
Our subsidiary in Germany, Hormosan, focuses on offering innovative drugs through to generics for affordable treatment of various acute and chronic diseases. We have made constant progress in select therapy areas including rare diseases in neurology, pain management, sexual health and HIV. As a pharmaceutical company, Hormosan is an integral part of German society, contributing with medication for optimal, guideline-compliant care for the individual patient.
Netherlands
Nanomi, our subsidiary in the Netherlands, is a leader in the field of microsphere and nanoparticle manufacture and development of long-acting release medicines. Its proprietary Microsieve technology guarantees cost-effective, highly controlled and reproducible production of these medicines. Through Nanomi, Lupin’s mission is to become a global leader in the field of complex injectables and introduce a wide portfolio of branded and generic products in key markets.
Mexico
Laboratorios Grin, our subsidiary in Mexico, is currently dedicated to the development, manufacture and commercialisation of ophthalmological products, proteolytic enzymes, oral antibiotics and antivertiginosis, among others. Its focus areas include visual health, food supplements, respiratory diseases, algology, male health and angiology. Products manufactured here are exported to seven countries in the region.
Brazil
Medquímica, Lupin’s subsidiary in Brazil, is one of the most prominent pharmaceutical companies in the region, manufacturing drugs that are high in quality, reliability and safety. Here, we manufacture solid and liquid medicines for five focus areas: over-the-counter (OTC), similar drugs , hospital, generics, and dietary supplements. Like every other Lupin manufacturing site, quality is of utmost importance and the Medquimica site has been awarded the certificate of Good Manufacturing Practices (GMP).
Canada
Lupin Pharma Canada Limited, established in Toronto & Montreal In 2014, is the Canadian subsidiary of Lupin Limited. We are committed to strengthening our branded product portfolio with the launch of additional medicines developed from our own research and manufacturing process, as well as through strategic brand acquisitions and licensing.